Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset "EL-22" for The Treatment of Obesity
Preclinical results of EL-22 from a 2022 study demonstrated physiological , physical , and functional improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy...